PMID- 27111283
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20230216
IS  - 1530-0307 (Electronic)
IS  - 0023-6837 (Linking)
VI  - 96
IP  - 7
DP  - 2016 Jul
TI  - Explant culture of sarcoma patients' tissue.
PG  - 752-62
LID - 10.1038/labinvest.2016.49 [doi]
AB  - Human sarcomas comprise a heterogeneous group of rare tumors that affect soft 
      tissues and bone. Due to the scarcity and heterogeneity of these diseases, 
      patient-derived cells that can be used for preclinical research are limited. In 
      this study, we investigated whether the tissue explant technique can be used to 
      obtain sarcoma cell lines from fresh as well as viable frozen tissue obtained 
      from 8 out of 12 soft tissue and 9 out of 13 bone tumor entities as defined by 
      the World Health Organization. The success rate, defined as the percent of 
      samples that yielded sufficient numbers of outgrowing cells to be frozen, and the 
      time to freeze were determined for a total of 734 sarcoma tissue specimens. In 
      552 cases (75%) enough cells were obtained to be frozen at early passage. Success 
      rates were higher in bone tumors (82%) compared with soft tissue tumors (68%), 
      and the mean time to freezing was lower in bone tumors (65 days) compared with 
      soft tissue tumors (84 days). Overall, from 40% of the tissues cells could be 
      frozen at early passage within <2 month after tissue removal. Comparable results 
      as with fresh tissue were obtained after explant of viable frozen patient-derived 
      material. In a selected number of bone and soft tissue sarcoma entities, 
      conventional karyotyping and/or FISH (fluorescence in situ hybridization) 
      analysis revealed a high amount (>60%) of abnormal cells in 41% of analyzed 
      samples, especially in bone sarcomas (osteosarcoma and Ewing sarcoma). In 
      conclusion, the explant technique is well suited to establish patient-derived 
      cell lines for a large majority of bone and soft tissue sarcoma entities with 
      adequate speed. This procedure thus opens the possibility for molecular analysis 
      and drug testing for therapeutic decision making even during patient treatment.
FAU - Muff, Roman
AU  - Muff R
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
FAU - Botter, Sander M
AU  - Botter SM
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
FAU - Husmann, Knut
AU  - Husmann K
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
FAU - Tchinda, Joelle
AU  - Tchinda J
AD  - Oncology Laboratory, University Children's Hospital Zurich, Zurich, Switzerland.
FAU - Selvam, Philomina
AU  - Selvam P
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
FAU - Seeli-Maduz, Franziska
AU  - Seeli-Maduz F
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
FAU - Fuchs, Bruno
AU  - Fuchs B
AD  - Laboratory for Orthopedic Research, Department of Orthopedics, University of 
      Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160425
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (Calmodulin-Binding Proteins)
RN  - 0 (EWSR1 protein, human)
RN  - 0 (RNA-Binding Protein EWS)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Bone Neoplasms/classification/genetics/*pathology
MH  - Calmodulin-Binding Proteins/genetics
MH  - Cell Line, Tumor
MH  - Cryopreservation
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Male
MH  - Proto-Oncogene Proteins c-mdm2/genetics
MH  - RNA-Binding Protein EWS
MH  - RNA-Binding Proteins/genetics
MH  - Sarcoma/classification/genetics/*pathology
MH  - Soft Tissue Neoplasms/classification/genetics/*pathology
MH  - Tissue Culture Techniques/*methods
EDAT- 2016/04/26 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/04/26 06:00
PHST- 2015/10/02 00:00 [received]
PHST- 2016/03/08 00:00 [revised]
PHST- 2016/03/03 00:00 [accepted]
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S0023-6837(22)01535-5 [pii]
AID - 10.1038/labinvest.2016.49 [doi]
PST - ppublish
SO  - Lab Invest. 2016 Jul;96(7):752-62. doi: 10.1038/labinvest.2016.49. Epub 2016 Apr 
      25.